A multidisciplinary approach to reproductive healthcare in women with rheumatic disease.

Introduction: Rheumatic disease (RD) patients when family planning must consider fertility, disease activity, and management from preconception to lactation. A clear understanding is necessary, especially for those receiving disease-modifying antirheumatic medications. Previous studies have highlighted unmet needs in the care of women with RDs with reproductive healthcare needs.

Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines.

Background: Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease which can cause significant disability, morbidity, mortality, and impaired fertility. It commonly affects women of childbearing age. Managing rheumatoid arthritis (RA) in the perinatal period poses challenges.

Fetal anhydramnios following maternal non-steroidal anti-inflammatory drug use in pregnancy.

We present a case report of transient fetal anhydramnios following maternal non-steroidal anti-inflammatory drug use in pregnancy. This reduction in liquor volume resolved following cessation of the medication with no obvious ill-effect on neonatal outcome. The case report is followed by a comprehensive summary of the relevant literature.

Development of the functional visual field.

Andries Sanders' dissertation examined selective mechanisms in the functional visual field, and much of his work since has been concerned with the stages that underlie visual information processing particularly while making saccades. We argue that the study of orienting in the functional visual field is timely because it deals with the relation of covert attention shifts, eye movements and head movements to their underlying neurology. In our paper we develop a method to study learning of sequences at all ages from infants to adults.

Modest doses of beta-glucan do not reduce concentrations of potentially atherogenic lipoproteins.

Background: In 1997, the US Food and Drug Administration passed a unique ruling that allowed oat bran to be registered as the first cholesterol-reducing food at a dosage of 3 g beta-glucan/d.

Objective: The effects of a low dose of oat bran in the background diet only were investigated in volunteers with mild-to-moderate hyperlipidemia.

Design: The study was a double-blind, placebo-controlled, randomized, parallel study.